ES2147519A1 - Utilizacion de un compuesto de tipo retinoide para modular in vivo la actividad desacopladora de la proteina ucp2. - Google Patents

Utilizacion de un compuesto de tipo retinoide para modular in vivo la actividad desacopladora de la proteina ucp2.

Info

Publication number
ES2147519A1
ES2147519A1 ES009801680A ES9801680A ES2147519A1 ES 2147519 A1 ES2147519 A1 ES 2147519A1 ES 009801680 A ES009801680 A ES 009801680A ES 9801680 A ES9801680 A ES 9801680A ES 2147519 A1 ES2147519 A1 ES 2147519A1
Authority
ES
Spain
Prior art keywords
decoupling
vivo
activity
modulate
type compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES009801680A
Other languages
English (en)
Other versions
ES2147519B1 (es
Inventor
Frederic Bouillaud
Daniel Ricquier
Zueco Eduardo Rial
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Consejo Superior de Investigaciones Cientificas CSIC
Original Assignee
Consejo Superior de Investigaciones Cientificas CSIC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Superior de Investigaciones Cientificas CSIC filed Critical Consejo Superior de Investigaciones Cientificas CSIC
Publication of ES2147519A1 publication Critical patent/ES2147519A1/es
Application granted granted Critical
Publication of ES2147519B1 publication Critical patent/ES2147519B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Utilización de un compuesto de tipo retinoide para modular in vivo la actividad desacopladora de la proteína UCP233. Esta invención se refiere a la utilización de un compuesto de tipo retinoide particularmente ácido retinoico para la preparación de un medicamento capaz de modular in vivo la actividad desacopladora de proteínas de desacoplamiento. Estos compuestos pueden utilizarse provechosamente para el tratamiento de enfermedades asociadas a un aumento o disminución de la actividad de proteínas de desacoplamiento. Según un modo de realización preferido, se utilizará el ácido retinoico para tratar enfermedades asociadas a una disminución de la actividad desacopladora de la proteína UCP2 como, por ejemplo, la obesidad.
ES009801680A 1997-08-05 1998-08-05 Utilizacion de un compuesto de tipo retinoide para modular in vivo la actividad desacopladora de la proteina ucp2. Expired - Fee Related ES2147519B1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9710009A FR2767058B1 (fr) 1997-08-05 1997-08-05 Utilisation d'un compose de type retinoide, notamment l'acide retinoique pour la preparation d' un medicament destine au traitement de l'obesite.

Publications (2)

Publication Number Publication Date
ES2147519A1 true ES2147519A1 (es) 2000-09-01
ES2147519B1 ES2147519B1 (es) 2001-03-16

Family

ID=9510039

Family Applications (2)

Application Number Title Priority Date Filing Date
ES009801680A Expired - Fee Related ES2147519B1 (es) 1997-08-05 1998-08-05 Utilizacion de un compuesto de tipo retinoide para modular in vivo la actividad desacopladora de la proteina ucp2.
ES98936435T Expired - Lifetime ES2189213T3 (es) 1997-08-05 1998-08-05 Utilizacion de un compuesto de tipo retinoide para aumentar in vivo la actividad de desacoplamiento de la proteina ucp2.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES98936435T Expired - Lifetime ES2189213T3 (es) 1997-08-05 1998-08-05 Utilizacion de un compuesto de tipo retinoide para aumentar in vivo la actividad de desacoplamiento de la proteina ucp2.

Country Status (9)

Country Link
US (2) US20030229143A1 (es)
EP (1) EP1018338B1 (es)
AT (1) ATE228362T1 (es)
AU (1) AU8543098A (es)
CA (1) CA2299270A1 (es)
DE (1) DE69809785T2 (es)
ES (2) ES2147519B1 (es)
FR (1) FR2767058B1 (es)
WO (1) WO1999007358A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576906B1 (en) 1999-10-08 2003-06-10 Symyx Technologies, Inc. Method and apparatus for screening combinatorial libraries for semiconducting properties
AU1763201A (en) * 1999-11-10 2001-06-06 Mitokor Modulation of mitochondrial mass and function for the treatment of diseases and for target and drug discovery
US6365796B1 (en) 2000-02-16 2002-04-02 Beth Israel Deaconess Medical Center Transgenic UCP2 knockout mouse and use thereof
AU2001251132A1 (en) * 2000-03-31 2001-10-15 University Technology Corporation Expression of uncoupling protein (ucp) in plants
US7105718B2 (en) 2000-03-31 2006-09-12 The Regents Of The University Of Colorado Compositions and methods for regulating metabolism in plants
ES2177404B1 (es) * 2000-07-07 2004-09-16 Consejo Superior De Investigaciones Cientificas Procedimiento para la determinacion de la actividad de las proteinas desacoplantes (ucps) mediante la monitorizacion del consumo de nad (p) h.

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5219888A (en) * 1992-03-31 1993-06-15 American Cyanamid Company Use of retinoids for the treatment of coronary artery disease
EP0579915A1 (de) * 1992-05-20 1994-01-26 F. Hoffmann-La Roche Ag Pharmazeutisches Präparat, enthaltend 9-cis- oder 13-cis-Retinsäure oder Acitretin und ein Vitamin-D-Derivat
WO1994026277A1 (en) * 1993-05-17 1994-11-24 Research Development Foundation Inhibition of tumor necrosis factor and nitric oxide production by retinoic acid
WO1995018533A1 (en) * 1994-01-04 1995-07-13 The Trustees Of The University Of Pennsylvania Methods and compounds affecting adipocyte differentiation and obesity
EP0698392A1 (fr) * 1994-08-02 1996-02-28 L'oreal Compositions contenant et ligand spécifique de RAR alpha et au moins un acide gras
WO1996024344A1 (en) * 1995-02-10 1996-08-15 Warner-Lambert Company USE OF RETINOIDS TO LOWER PLASMA LEVELS OF LIPOPROTEIN (a)
EP0749752A1 (fr) * 1995-06-19 1996-12-27 Centre International De Recherches Dermatologiques Galderma (C.I.R.D. Galderma) Utilisation de ligands spécifiques des récepteurs RXRs
WO1997010819A1 (en) * 1995-09-18 1997-03-27 Ligand Pharmaceuticals Incorporated Treating niddm with rxr agonists

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5051449A (en) * 1991-02-27 1991-09-24 Kligman Albert M Treatment of cellulite with retinoids

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5219888A (en) * 1992-03-31 1993-06-15 American Cyanamid Company Use of retinoids for the treatment of coronary artery disease
EP0579915A1 (de) * 1992-05-20 1994-01-26 F. Hoffmann-La Roche Ag Pharmazeutisches Präparat, enthaltend 9-cis- oder 13-cis-Retinsäure oder Acitretin und ein Vitamin-D-Derivat
WO1994026277A1 (en) * 1993-05-17 1994-11-24 Research Development Foundation Inhibition of tumor necrosis factor and nitric oxide production by retinoic acid
WO1995018533A1 (en) * 1994-01-04 1995-07-13 The Trustees Of The University Of Pennsylvania Methods and compounds affecting adipocyte differentiation and obesity
EP0698392A1 (fr) * 1994-08-02 1996-02-28 L'oreal Compositions contenant et ligand spécifique de RAR alpha et au moins un acide gras
WO1996024344A1 (en) * 1995-02-10 1996-08-15 Warner-Lambert Company USE OF RETINOIDS TO LOWER PLASMA LEVELS OF LIPOPROTEIN (a)
EP0749752A1 (fr) * 1995-06-19 1996-12-27 Centre International De Recherches Dermatologiques Galderma (C.I.R.D. Galderma) Utilisation de ligands spécifiques des récepteurs RXRs
WO1997010819A1 (en) * 1995-09-18 1997-03-27 Ligand Pharmaceuticals Incorporated Treating niddm with rxr agonists

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FLEURY, CH. y col. Uncoupling protein-2: a novel gene linked to obesity and hyperinsulinemia. Nature Genetics, Marzo 1997, Vol. 15, No 3, paginas 269-272. *
KUMAR, M.V. y SCARPACE, P.J. DIFFERENTIAL EFFECTS OF RETINOIC ACID ON UNCOUPLING PROTEIN AND LEPTIN GENE EXPRESSION. FASEB JOURNAL, Abril 1997, Vol. 11, No 3, pagina A374; resumen 2165. *
PUIGSERVER, P. y col. In vitro and in vivo induction of brown adipocyte uncoupling protein (thermogenin) by retinoic acid. Biochemical Journal, 1996, Vol. 317, No 3, paginas 827-833. *
WOLF, G. A Regulatory Pathway of Thermogenesis in Brown Fat Through Retinoic Acid. Nutrition Reviews, 1995, Vol. 53, No 8, paginas 230-231. *

Also Published As

Publication number Publication date
FR2767058B1 (fr) 2000-05-05
WO1999007358A1 (es) 1999-02-18
FR2767058A1 (fr) 1999-02-12
DE69809785D1 (de) 2003-01-09
ES2147519B1 (es) 2001-03-16
CA2299270A1 (en) 1999-02-18
EP1018338A1 (en) 2000-07-12
EP1018338B1 (en) 2002-11-27
US20030229143A1 (en) 2003-12-11
ATE228362T1 (de) 2002-12-15
AU8543098A (en) 1999-03-01
ES2189213T3 (es) 2003-07-01
DE69809785T2 (de) 2003-09-18
US20070015830A1 (en) 2007-01-18

Similar Documents

Publication Publication Date Title
DE69815323D1 (de) Therapeutische nahrung für diabätiker
MX9606404A (es) Composiciones farmaceuticas y metodos para formular trasnduccion de señales.
HUP9700603A1 (hu) Gyógyászati készítmény véralvadási zavarok kezelésére
ATE262336T1 (de) Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa- 4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14- dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen
AU3368497A (en) Human dnase i hyperactive variants
PT913156E (pt) Utilizacao de proteina c activada para tratar estados hipercoagulaveis associados com sepsia
ATE254910T1 (de) Doppelkapsel zur verabreichung von arzneimitteln für vielfache therapien
ATE493978T1 (de) Behandlung von autoimmunerkrankungen
BR9816013A (pt) Proteìna de ligação de interleucina-18
AU5911499A (en) Leptin induced genes
LU93259I2 (fr) LETIFEND (Protein Q)
WO2003062273A3 (en) Modulator of the notch signalling pathway and use thereof in medical treatment
NZ332954A (en) Use of BPI protein products to treat humans with hemorrhage due to trauma
DE69725879D1 (de) VERWENDUNG VON p-AMINOPHENOLDERIVATEN ZUR HERSTELLUNG VON PHARMAZEUTISCHEN ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON NEURODEGENERATIVEN ERKRANKUNGEN
ES2147519A1 (es) Utilizacion de un compuesto de tipo retinoide para modular in vivo la actividad desacopladora de la proteina ucp2.
EP1108429A3 (en) An improved amino acid composition for providing an amino acid supplement or protein substitute, particularly for the treatment and/or management of certain diseases
WO2001043705A3 (en) Compositions containing a retinoid and a stilbene for skin care
BR9804921A (pt) Peptìdeo natriurético atrial (anp) como um aditivo para soluções de diálise peritoneal.
NO933742L (no) Humant, benavledet, insulinlignende vekstfaktorbindingsprotein
WO1996032134A3 (de) Konjugat aus einem wirkstoff, einem polyether und ggf. einem nicht als körperfremd angesehenen, nativen protein
ATE317021T1 (de) Antisense modulierung von lfa-3
WO1999050671A3 (en) Toso as a target for drug screening
DE69000791D1 (de) Therapeutische mittel fuer metabolische knochenkrankheiten.
DE59607417D1 (de) Konjugat zur behandlung von entzündungserkrankungen
AU7079300A (en) Compositions and methods for the treatment of immune related diseases

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20000901

Kind code of ref document: A1

Effective date: 20000901

FD2A Announcement of lapse in spain

Effective date: 20180807